Navigation Links
Abbott to Present Data on Novel Cancer Treatments at American Society of Clinical Oncology Annual Meeting
Date:5/15/2008

3.5 hours. In seven out of 20 cases (35 percent), DP-PS correctly predicted the eventual outcome. These results seem to indicate that PS derived from DP model showed better correlation with drug exposure and could predict patient outcome better than Ktrans.

In a separate analysis, the effects of ABT-869 on biomarkers of angiogenesis were evaluated. Correlations of dose and pharmacokinetics of ABT-869, with serum biomarkers, tumor DCE-MRI tracer kinetics, proteinuria and hypertension were assessed. Results appeared to indicate that ABT-869 induced dose-dependent changes in serum biomarkers are consistent with anti-angiogenic activity. However, these serum biomarkers had limited value in predicting safety, i.e., proteinuria or hypertension. The utility of tumor flow and permeability changes on DCE-MRI in predicting proteinuria should be further examined. Updated information will be presented at the ASCO Annual Meeting.

Background on Abbott's Oncology Pipeline

Bcl-2 Family Protein Inhibitors (ABT-263)

Researchers have been interested in the Bcl-2 family of proteins since their role in preventing apoptosis -- the natural process by which damaged or unwanted cells die and are cleared from the body -- was proven more than a decade ago. Discovered by Abbott scientists, ABT-263 restores programmed cell death, a natural mechanism for the elimination of cancerous cells, by inhibiting the function of Bcl-2 proteins.

Bcl-2 proteins play a central role in regulating apoptosis, as well as tumor formation, tumor growth and resistance to treatment. Pioneering work in structural biology at Abbott established how the Bcl-2 family proteins interact with one another, leading researchers to develop a novel compound that causes cancer cells to self-destruct.

ABT-263 is in Phase I/II clinical trials for lymphomas and solid tumors, including small cell lung cancer. Preclinical data has shown that Abbott's Bcl-2 family protein inhibitors bind to Bc
'/>"/>

SOURCE Abbott
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. Abbott to Present at Citi Investment Research Global Health Care Conference
2. Abbott to Present at Morgan Stanley Global Healthcare Unplugged Conference
3. Abbott Announces HUMIRA(R) (adalimumab) Approved in Japan for the Treatment of Rheumatoid Arthritis
4. Abbott Reports Double-Digit Sales and Earnings Growth in First Quarter and Reaffirms Full-Year Growth Outlook
5. Innovative Diagnostic Instrument Introduced by Abbott for Low- to Mid-Volume Laboratory Market Segment
6. Abbott FreeStyle Freedom(R) Lite Blood Glucose Monitoring System Now Available With No Coding for People With Diabetes
7. Abbott Hosts Conference Call for First-Quarter Earnings
8. Takeda, Abbott Announce Plans to Conclude TAP Joint Venture
9. FDA Approves Abbotts FreeStyle Navigator(R) Continuous Glucose Monitoring System
10. Abbott Receives CE Mark for Smaller-Size XIENCE(TM) V Drug Eluting Stent
11. Abbott, Genentech and WEHI Collaborate to Research and Develop New Anti-Cancer Drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... is a famous wedding dress company offering many trendy designs. ... Facebook, Twitter, and Pinterest. The fans will have an opportunity ... every week. , Moreover, the company has extended its 2015 ... homepage for more information. , Angelweddingdress is a ...
(Date:1/22/2015)... York, New York (PRWEB) January 22, 2015 ... http://www.vaginalmeshlawsuit2015.com/ ) in the U.S. District Court, Southern District of ... C.R. Bard, Inc. in that proceeding’s first bellwether trial. In ... request for a new trial after finding that C.R. Bard ...
(Date:1/22/2015)... New York, New York (PRWEB) January 22, 2015 ... filed after Fresenius Medical Care recalled its GranuFlo ... the federal multidistrict litigation underway in U.S. District Court, ... an Order dated January 20th, the Court has remanded ...
(Date:1/22/2015)... 2015 Carinsurancesavings.biz has released a new blog ... dismemberment insurance . , Purchasing an accidental death and ... advantageous. This type of rider provides benefits if the insured ... considered a lesser form of life insurance. , AD&D ...
(Date:1/22/2015)... Calif. (PRWEB) January 22, 2015 ... Susan Bonilla (D-Concord) and Kristin Olsen (R-Modesto) were ... their leadership in advancing biotechnology, biomedical science, medical ... and Olsen each received the “2014 Life Sciences ...
Breaking Medicine News(10 mins):Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Accidental Death and Dismemberment Insurance Can Be Purchased at Low Prices Online 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3
... , ... Another Group Logic Solution to Their Product Portfolio , ... (PRWEB) March 24, 2010 -- Group Logic, the ... the United Kingdom, Jigsaw Systems, is adding the MassTransit product line to its solution ...
... cases are few after time, but death risk is ... (HealthDay News) -- Breast cancer recurrence in the same ... predictor of subsequent cancer spread and death in patients ... study has found. , Researchers analyzed data from 7,749 ...
... ... questioned if the HCG diet can be harmful. Dr Robert True addresses this issue and ... ... sees patients on a daily basis that he helps lose weight through his HCG Diet program. ...
... This release is available in Spanish . ... at the link between socioeconomic status and survival after breast ... outcomes and that this is only partly explained by more ... that lower socioeconomic status is linked with women consulting their ...
... Barcelona, Spain: Many patients with metastatic breast ... treatment should be to prolong life by at least a ... best therapies, a researcher will tell the seventh European Breast ... with doctors, perception that an additional four to six months, ...
... the aches and pains that occur in old age, many ... from their past. A new study, reported in the ... ), reveals that older adults, ability to remember the past ... which the brain processes emotional content. In the older ...
Cached Medicine News:Health News:Jigsaw Systems to Deliver Group Logic's MassTransit Solution for Managed File Transfer 2Health News:Breast Cancer's Return in Original Tumor Site a Bad Sign 2Health News:HCG True Diet – Dr. Robert True Speaks About the Importance of Medical Supervision for HCG Diets 2Health News:Worse breast cancer outcomes for women from poorer backgrounds are not due to late diagnosis alone 2Health News:Worse breast cancer outcomes for women from poorer backgrounds are not due to late diagnosis alone 3Health News:What should be the goal of treatment in metastatic breast cancer? 2Health News:What should be the goal of treatment in metastatic breast cancer? 3Health News:Older adults remember the good times 2
(Date:1/23/2015)... , Jan. 23, 2015  Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT), ... I trial of Lixte,s lead compound, LB‑100, is being conducted, ... John S. Kovach , M.D., the founder and President ... be completed at a single site. Accrual of patients, however, ...
(Date:1/23/2015)... MONMOUTH JUNCTION, N.J. , Jan. 23, 2015 ... immunotherapy company commercializing its CytoSorb® extracorporeal cytokine adsorber ... surgery patients, announced the receipt of $385,642, net ... approved participant of the Technology Business Tax Certificate ...
(Date:1/23/2015)... and BOSTON , January 23, 2015 ... and development company, is delighted to announce that the ... to Miles Congreve (Vice President of Chemistry), ... Malcolm Weir (Chief Executive Officer and co-founder) for the ...
Breaking Medicine Technology:Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 2CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 3Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 2Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 3Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 4
... 24, 2011 Veridex, LLC today announced the launch ... research scientists with a fast, convenient and reliable way ... technology to capture and count CMCs, the CELLTRACKS® CMC ... engineering investigational therapies that are based on a specific ...
... Omeros Corporation (NASDAQ: OMER ) today ... Office (USPTO) of an additional patent claiming the composition ... 3 clinical development.  The patent will have a term ... extends coverage for OMS103HP and adds to our established ...
Cached Medicine Technology:Veridex Launches CELLTRACKS® Circulating Melanoma Cell Kit for Research Use 2Veridex Launches CELLTRACKS® Circulating Melanoma Cell Kit for Research Use 3Omeros Reports Allowance of Additional Patent for Arthroscopic Product 2Omeros Reports Allowance of Additional Patent for Arthroscopic Product 3
HemoNIR™ is a portable device that measures the ability of apersons blood to carry oxygen by monitoring functional vs. non functional hemoglobin....
... real-time PCR analysis of gene expression ... LightCycler 480 System combines amazing speed ... the needs of a broad range ... including array validation, gene-knockdown studies, and ...
... Vivid 3 - Vivid family system ... level of cardiovascular performance, and offer an ... vascular, pediatrics and the OR. , ,From ... to DICOM connectivity, the new Vivid 3 ...
... Wireless, internet-based ... provides compliance and ... complete system. The ... System incorporates communication ...
Medicine Products: